China Aoxing Pharmaceutical Company Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
23 July 2009 - 10:00PM
Marketwired
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China
Aoxing"), a China-based pharmaceutical company specializing in
research, development, manufacturing and distribution of narcotic
and pain-management products, today announced that it has received
renewal of the Good Manufacturing Practice (GMP) certification for
its capsule formulation and packaging production facility. The
certificate of compliance has a five-year term and was issued by
the State Food and Drug Administration (SFDA) following a site
inspection.
"Good Manufacturing Practice" is a body of internationally
accepted regulations set forth by drug agencies at many countries.
GMP compliance ensures that pharmaceuticals, active ingredients and
medical devices are produced and quality-controlled according to
state-of-the-art standards. According to the National Medicine
Administration Law of the People's Republic of China, all
pharmaceutical manufacturers must pass an examination every five
years to renew their GMP Certificates.
"GMP compliance is the gold standard in quality assurance in the
life science industry. We are happy to obtain the renewal of the
GMP certificate for capsule products," said Juan Yue Han, Chairman
and the CEO of China Aoxing. "This provides the foundation for the
further development of China Aoxing. We are well positioned to
manufacture pharmaceutical products in capsule dosage form to
address significantly unmet medical needs in the areas of cancer
pain, acute and chronic pain, as well as other neurological
disorders."
About China Aoxing Pharmaceutical Company, Inc.
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) is a
pharmaceutical company located in China specializing in research,
development, manufacturing and distribution of a variety of
narcotics and pain-management products. It has a strategic alliance
with American Oriental Bioengineering, Inc. (NYSE: AOB) to develop
and market various narcotic drugs in China. Headquartered in
Shijiazhuang City, the pharmaceutical capital of China, outside of
Beijing, China Aoxing has China's largest and the most advanced
manufacturing facility for highly regulated narcotic medicines,
addressing a very under-served and fast-growing market in China.
Its facility is one of the few GMP facilities licensed for
narcotics medicines. The Company is working closely with the
Chinese government and SFDA to assure the strictly regulated
availability to medical professionals of its narcotic drugs and
pain medicines throughout China.
Statements made in this press release are forward-looking and
are made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve risks and
uncertainties that may cause actual results to differ materially
from those set forth in these statements. The economic,
competitive, governmental, technological and other risk factors
identified in the Company's filings with the Securities and
Exchange Commission, including the Form 10-KSB for the year ended
June 30, 2008, may cause actual results or events to differ
materially from those described in the forward looking statements
in this press release. The Company undertakes no obligation to
publicly update or revise any forward-looking statements, whether
because of new information, future events, or otherwise.
Contact: Wei Zhang China Aoxing Pharmaceutical Company, Inc.
Email: chinaaoxing@gmail.com Telephone: 646-367-1747 Website:
www.chinapainmed.com
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jun 2024 to Jul 2024
American Oriental Bioengineering, Inc. (NYSE:AOB)
Historical Stock Chart
From Jul 2023 to Jul 2024